Biotech is in Play – OSI Pharmaceuiticals
The 50% premium being paid for OSIP by Astellas, which is roughly $52/share, was actually rejected by the board. The market is pricing the stock at $56, and I think the stock climbs another $10 from here. There will be another bidder. The M&A attention is bullish for the sector. There are some good plays [...]
